The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The History of Treating Lupus with Hydroxychloroquine

The History of Treating Lupus with Hydroxychloroquine

June 15, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Given how unexpectedly front and center hydroxychloroquine has been in discussions about the treatment of COVID-19 this year, it makes sense to look at how it became so central to the treatment of a rheumatologic condition.

You Might Also Like
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
Explore This Issue
June 2020
Also By This Author
  • How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

In 1991, an article appeared in The New England Journal of Medicine that would alter the way rheumatologists approached treatment for systemic lupus erythematosus: “A Randomized Study of the Effects of Withdrawing Hydroxychloroquine Sulfate in Systemic Lupus Erythematosus.”1 Although questions remained about optimal dosing, the study opened the way for much follow-up research that would confirm the drug’s critical importance for lupus patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Antimalarials: Background

Scientists synthesized the first antimalarial drugs shortly before the start of World War II. Malaria was a leading cause of death among soldiers, particularly in the South Pacific. The first antimalarial, quinacrine, produced numerous side effects, prompting researchers to develop derivate compounds. The U.S. Army introduced chloroquine, one of these compounds, in 1943.2

In 1951, Francis Page, MD, reported that quinacrine had beneficial effects on lupus symptoms.3 A similar report appeared two years later, when James Charles Shee, MD, published findings demonstrating that soldiers with rheumatoid arthritis (RA) or lupus taking chloroquine showed clinical improvement.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michelle Petri, MD, MPH, co-director of the Johns Hopkins Lupus Center and a professor of medicine at Johns Hopkins School of Medicine, Baltimore, elaborates on the discovery of the drug’s use in inflammatory conditions. “The military personnel who had rheumatoid arthritis and lupus felt much better when they were taking the malaria medicine and then wanted to continue it when they left the military,” she explains. “It’s almost a discovery made accidentally, as so many medical discoveries are. It’s a nice story of physicians listening to their patients.”

Modifications to chloroquine eventually led to the introduction of an anti­malarial purported to have fewer side effects, hydroxychloroquine, which the U.S. Food & Drug Administration (FDA) approved in 1955.2 The most commonly reported adverse effects of antimalarials are mild, such as gastrointestinal discomfort or headache. However, other concerns about the safety of antimalarials emerged over time, partly because doses for rheumatological conditions were much higher than those used for malaria prophylaxis.

A population-based, case-controlled study from 2019 demonstrated that the mortality risk increased almost fourfold in people who had to stop taking their hydroxychloroquine. It is the only drug that has been demonstrated to improve the survival of lupus patients.

In the late 1950s, reports began to appear documenting retinopathy resulting from chloroquine treatment.5 This important potential adverse effect continues to influence prescribing practices to this day.

Both chloroquine and hydroxychloroquine can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to retinopathy.6 Eventually, research demonstrated that hydroxychloroquine posed less of a risk of retinopathy than chloroquine.

In the U.S. and Canada, hydroxychloroquine has largely replaced chloroquine as a treatment for lupus in the antimalarial drug class.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Lost & Found, retinopathy, SLE Resource CenterIssue: June 2020

You Might Also Like:
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
  • Reflections on Living with Lupus, and on Treating It

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at www.ruthjhickmanmd.com.

View more by this author»

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.